Ulysses Neuroscience is dedicated to advancing the understanding and treatment of rare neurodevelopmental, psychiatric, and neurodegenerative disorders through a robust commitment to translational research. Their research capabilities encompass both clinical and preclinical platforms, utilizing a variety of therapeutic interventions and extensive biomarker analyses. The company employs advanced methodologies, including in-vivo disease models such as genetically modified mice for conditions like Fragile X Syndrome and Angelman syndrome, as well as sophisticated behavioral analysis techniques to assess cognitive and motor functions. Their research also integrates fluid biomarker analysis to enhance the understanding of druggable targets and epidemiological characteristics, thereby improving the efficacy of pharmaceutical studies.

In addition to their in-vivo research, Ulysses Neuroscience utilizes cutting-edge in-vitro techniques, including primary culture systems and induced pluripotent stem cells (iPSCs) to study neuroprotective mechanisms and disease pathology. Their facilities are equipped for advanced neurochemical measurements using amperometry and voltammetry, allowing for real-time monitoring of neurotransmitter dynamics in freely-moving animal models. The company emphasizes ethical compliance in all its research practices, ensuring that both clinical and preclinical studies adhere to the highest standards of scientific integrity and animal welfare. Through these comprehensive research strategies, Ulysses Neuroscience aims to bridge the gap between laboratory findings and clinical applications, ultimately prioritizing patient needs in the drug development process.

Ireland

Ulysses Neuroscience Limited is an Irish Private R&D Organisation providing clinical and preclinical research services to pharmaceutical companies.

Ulysses Neuroscience

Company Details